The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EMN 2018 | Multiple myeloma subgroups for risk-adapted therapy
The contemporary viewpoint is that multiple myeloma (MM) is a group of separate diseases, rather than just one type of cancer. This has allowed patients to be grouped according to their specific form of MM and receive treatment tailored to their subtype. In this video, recorded at the 1st European Myeloma Network Meeting (EMN) held in Turin, Italy, Vittorio Montefusco, MD, of the IRCCS Foundation, National Cancer Institute of Milan, Milan, Italy, describes some of the different subgroups of patients, how they are defined and what treatments are being developed for each of these groups.
